Table 1.
Clinical and radiological findings, respiratory assessment, and complications of H1N1 infected children. In bold the more severe H1N1 patients.
| Patients | Fever at first day of admission | Duration of cough (days) | SpO2 at admission in room air | Chest X-ray | Respiratory care | Antimicrobial therapy | Complications | Length of stay in hospital (days) | Outcome (GOS) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39.6 ± 0.5 | 8 | 78% | Pneumothorax | O 2 supplementation by Ventimask | Ceftriaxone, Clarithromycin, and Oseltamivir | None | 11 | 5 |
|
| |||||||||
| 2 | 39.7 ± 0.4 | 6 | 78% | Pneumonia | CPAP by Helmet (1 day) + O 2 by Ventimask | Ceftriaxone, Oseltamivir | None | 10 | 5 |
|
| |||||||||
| 3 | 39.1 ± 0.6 | 8 | 70% | Interstitial pneumonia, pleural effusion | NIV by full-face mask, EI/MV (2 days ), CPAP by Helmet (4 days) | Ceftriaxone, Clarithromycin, and Oseltamivir | Pneumorrachis | 19 | 5 |
|
| |||||||||
| 4 | 39.3 ± 0.6 | 6 | 81% | Pneumonia | O 2 supplementation by Ventimask | Ceftriaxone, Oseltamivir | None | 9 | 5 |
|
| |||||||||
| 5 | 39.4 ± 0.7 | 7 | 82% | Bilateral pulmonary infiltrates | O 2 supplementation by Ventimask | Ceftriaxone, Oseltamivir | None | 9 | 5 |
|
| |||||||||
| 6 | 39.2 ± 0.4 | 7 | 50% | Bilateral pulmonary consolidation | EI/MV (11 days), CPAP by Helmet (4 days) | Ceftriaxone, Clarithromycin, and Oseltamivir | None | 27 | 5 |
|
| |||||||||
| 7 | 39.7 ± 0.6 | 6 | 76% | Bilateral pulmonary infiltrates | O 2 supplementation by Ventimask | Ceftriaxone, Oseltamivir | Pneumomediastinum | 11 | 5 |
|
| |||||||||
| 8 | 39.2 ± 0.3 | 5 | 82% | Pneumonia | O 2 supplementation by Ventimask | Ceftriaxone, Oseltamivir | Pneumopericardium | 18 | 5 |
|
| |||||||||
| 9 | 39.5 ± 0.4 | 9 | 73% | Pneumothorax, bilateral pulmonary consolidation | NIV by full-face mask | Ceftriaxone, Oseltamivir | None | 18 | 5 |
|
| |||||||||
| 10 | 38.5 ± 0.5 | 7 | 90 | Interstitial pneumonia | O2 supplementation | Klaritromicin, Oseltamivir | None | 7 | 5 |
|
| |||||||||
| 11 | 38.7 ± 0.2 | 4 | 92 | Normal | O2 supplementation | Oseltamivir | None | 4 | 5 |
|
| |||||||||
| 12 | 38.2 ± 0.4 | 5 | 94 | Normal | None | Oseltamivir | None | 3 | 5 |
|
| |||||||||
| 13 | 38.3 ± 0.7 | 5 | 95 | Normal | None | Oseltamivir | None | 3 | 5 |
|
| |||||||||
| 14 | 38.4 ± 0.6 | 6 | 91 | Hyperinflated lung | O2 supplementation | Oseltamivir | None | 6 | 5 |
|
| |||||||||
| 15 | 38.1 ± 0.4 | 6 | 93 | Normal | None | Oseltamivir | None | 3 | 5 |
CPAP: continuous positive airway pressure; EI: endotracheal intubation; MV: mechanical ventilation.